U.S. License Holder:
Merz Pharms.
Date of License:
July-30-2010
Last Update:
Sep-30-2024
FDA-Approved Indications
XEOMIN (incobotulinumtoxinA) is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the treatment or improvement of:
Chronic sialorrhea in patients 2 years of age and older;
Upper limb spasticity in adults;
Upper limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy;
Cervical dystonia in adults;
Blepharospasm in adults;
The appearance of upper facial lines in adults:
Moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity; Moderate to severe horizontal forehead lines associated with frontalis muscle activit; Moderate to severe lateral canthal lines associated with orbicularis oculi muscle activity.